Silver Book Fact

Between 1988 & 1994 and 1999 & 2004, use of pharmacological lipid-lowering treatment increased from 11.7% to 40.8%. Low-density lipoprotein cholesterol control increased from 4.0% to 25.1% among those with
high low-density lipoprotein cholesterol.

Rosamond W, Flegal K, Furie K, Go A, et al. Heart Disease and Stroke Statistics- 2008 Update. Circulation. 2008; 117. http://circ.ahajournals.org/cgi/content/short/117/4/e25

Reference

Title
Heart Disease and Stroke Statistics- 2008 Update
Publication
Circulation
Publication Date
2008
Authors
Rosamond W, Flegal K, Furie K, Go A, et al
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • t-PA cost savings
    The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
  • Per-patient annual cost of treating stroke in atrial fibrillation patients
    The per-patient annual cost of treating stroke in atrial fibrillation patients was found to be $1,485 in a wellcontrolled anti-coagulation clinic, $3,710 for those receiving warfarin in routine medical care,…  
  • Ischemic stroke patients treated with t-PA (a drug used to treat blood clots) within 3 hours of onset are 33% more likely to be free of disability 3 months after…  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • New approaches are under development to reduce ischemic stroke damage and other damage occuring because of stroke.